What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Actinogen Medical Limited announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem®/UE2343 once-a-day small molecule in ...

The mechanism of action for tirzepatide involves appetite regulation and improved satiety, allowing users to feel full with smaller portions. This can lead to sustainable weight loss when combined ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The timeline puts Novo on another collision course with Lilly, which told investors in October that it would file for FDA approval of tirzepatide ... offer a novel mechanism of action, enhanced ...

NAD+ IonToPatch – Utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption. The latex ...

Newer GLP-1 receptor agonists like tirzepatide, (which combines a ... that we see are predictable when you understand the mechanism of action of these drugs,” Coviello told Salon.

which makes tirzepatide, a more effective alternative, have together added around $1trn in market value since 2021. The action is now moving beyond America. With over two-fifths of the world ...

CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro ... in over 30 years with a ...